P2RY12 and coronary artery disorder: In addition, while aspirin has been the cornerstone of secondary prevention in patients with CAD undergoing PCI, novel evidence has shown that P2Y12 inhibitor monotherapy may improve net clinical benefit compared to aspirin monotherapy in selected populations.